Back

News

Category

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

June, 2024. During its participation in ASCO, XENOTHERA….

Read More

Reflections on #AACR2024: our key insights and contributions

April, 2024. The AACR Annual Meeting in San Diego was a pivotal...

Read More

XENOTHERA announces the start of the second dose cohort in the FIPO trial

March, 2024. FIPO is the first-in-human trial of XON7, the first anti-solid...

Read More

XENOTHERA : publication of the first-in-human trial of LIS1 in Solid Organ Transplantation

February, 2024. For almost ten years, XENOTHERA has been committed to tackling...

Read More

[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment

November 27, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] French biotech announces its therapeutic potential for oxygen-free patients

October 25, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] XENOTHERA strengthens its management team and governance.

June 8, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.

May 30, 2023. # Download our press release (english version) # Télécharger...

Read More

[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.

April 5,2023. # Télécharger notre communiqué de presse (version française)  

Read More

[Press Release] The French biotech XENOTHERA, on a mission with business France in China

April 3, 2023. # Download our press release (english version) # Télécharger...

Read More

[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

January 05,2023. # Download our press release (english version)  

Read More

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

Read More

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

December 19, 2022. # Download our press alert (english version) # Télécharger...

Read More

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

December 16,2022. # Download our press release (english version) # Télécharger notre...

Read More

[Newsletter] XENONEWS

November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

Read More

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

Read More

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

May 2022. # Download our press information (english version) # Télécharger notre...

Read More

[Press Alert] Safety and efficacy results of LIS1

June 2022. # Download our press information (english version) # Télécharger notre...

Read More

[ Press Information ] APPOINTMENTS

April 2022. # Download our press information (english version) # Télécharger notre...

Read More

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

January 2022. # Download our press information (english version) # Télécharger notre...

Read More

[ Press Information ]The French biotech XENOTHERA awarded Start-Up of the Year for the Western region.

# Download our press information (english version) # Télécharger notre information presse...

Read More

[Newsletter] XENONEWS

October 2021 >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

Read More

[Press Release] Accelarated Scientific Advise from European Medicines Adgency EMA for XAV19 Market Authorisation

July 8, 2021. # Download our press release (english version) # Télécharger...

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@izsogood.co

Linkedin-in